FDA Clears Ceribell for Quantitative EEG Trending and aEEG

Ceribell has received FDA 510(k) clearance for quantitative EEG trending and amplitude-integrated EEG (aEEG) analysis, adding two established neurophysiology display methods to its portable rapid-EEG platform.

The clearance covers software functionality that processes continuous scalp EEG recordings into compressed trend displays — the same analytical approach long used in neonatal and adult neurocritical care with conventional bedside monitors. Quantitative EEG (qEEG) trending compresses hours of raw multichannel EEG into panel views that let clinicians track seizure burden, symmetry, and periodic pattern evolution over time. Amplitude-integrated EEG presents a compressed, filtered amplitude envelope that supports rapid visual assessment of background suppression and ictal activity.

For readers of raw EEG, the distinction matters. These are not new signal-detection algorithms; they are display and trending methods with decades of clinical use, now integrated into Ceribell's FDA-cleared rapid EEG system. A 510(k) clearance means the FDA found the new functionality substantially equivalent to predicate devices — a regulatory pathway distinct from the De Novo or PMA routes used for wholly novel diagnostic claims.

The practical implication centers on where and how quickly neurophysiology expertise reaches the patient. Ceribell's platform is designed for point-of-care use — placement by non-specialists at the bedside, with recording and review that does not wait for a scheduled conventional EEG hookup. Adding qEEG trending and aEEG to that workflow means monitoring-unit staff can view compressed trends of long recordings and target raw-EEG review to the segments that matter most, rather than scrolling through hours of multichannel data.

That workflow mirrors what quantitative trends already deliver in ICUs running conventional continuous EEG: faster identification of nonconvulsive seizure burden, earlier recognition of delayed cerebral ischemia through asymmetry indices in appropriate populations, and a compressed format that supports communication between technologists, epileptologists, and intensivists. The value proposition here is delivering those same trend views on a device deployed outside the traditional EEG lab.

The clearance also reflects a broader shift in how critical-care EEG gets read. Continuous scalp EEG generates more data than any reading room can review page by page. Trend panels — seizure burden meters, amplitude-integrated traces, spectrogram arrays — have become the standard triage layer between the raw signal and the interpreter. Regulatory clearance of these trending tools on a portable platform signals that the FDA recognizes compressed trending as a core, rather than ancillary, function of modern neurodiagnostic devices.

What remains to be seen is how the new trending and aEEG capabilities perform in real-world deployment — published clinical experience with conventional qEEG trending does not automatically transfer to every hardware and electrode configuration, and validation data specific to this implementation will determine how confidently reading rooms can incorporate it into existing review protocols.

For now, the clearance gives monitoring units one more FDA-cleared option for quantitative display of continuous EEG at the point of care, and gives epileptologists a familiar analytical format on an increasingly common bedside platform.